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Summary  
Glioblastomas (GBM), a grade IV astrocytoma, is the most common and aggressive primary 
brain tumors in adults, associated with short survival and uniformly fatal outcome 
irrespective of treatment. GBM is highly heterogeneous at both molecular and histological 
levels, including pseudopalisading necrosis, that make GBM most hypoxic and angiogenic 
tumor in nature. Recent transcriptomic profiling has identified 4 distinct subtypes of GBM 
based on specific gene expression pattern. Of these the mesenchymal GBM subtype was 
reported to be the most aggressive one with the worst clinical outcome. Caveolin-1 (Cav-1) is 
well known principle scaffolding protein in caveole that directly interacts with several 
signalling molecules and play crucial role in numerous signalling pathways. Over the past 
10-15 years, Cav-1 has been found to have oncogenic and metastasis promoting roles in many 
aspects depending on the tumour type or tissue of interest.   
Within our project we investigated the role of a hypoxic microenvironment on Cav-1 
expression and on mesenchymal and proneural markers by western blotting. Our 
preliminary data indicate that Cav-1 is elevated under hypoxia in a fraction of GBM cell lines. 
Upregulation of Cav-1 was confirmed in GBM patient samples around necrotic areas, 
however, expression pattern of Cav-1 showed inter- and intra-tumoral heterogeneity. Despite 
the heterogeneity, Cav-1 expression was found to be highly upregulated in hypoxic regions 
in most of GBM samples, indicating a possible connection between hypoxia and Cav-1 
expression. TCGA patient data indicated a correlation of Cav-1 with mesenchymal markers 
and anti-correlation with proneural markers. Thus, we further investigated whether hypoxia 
induced a proneural to mesenchymal switch in GBM cell lines. Proneural markers PDGFRA 
and olig2 were downregulated under hypoxia, however no clear pattern for the 
mesenchymal markers YKL40, pSTAT3 and CD44 was observed.  
In conclusion, our results show that Cav-1 is upregulated under hypoxia in a subset of GBM, 
which parallels downregulation of proneural markers. Whether a mesenchymal shift is 
induced under hypoxia and whether this might be dependent on Cav-1 needs to be 





Cancer is a group of diseases that can affect most organs of the body and is caused by 
mutations in the genome of normal cells. Cancer development is a multistep process caused 
by successive changes, such as a series of genetic mutations in the DNA of one cell, inhibition 
of cell differentiation and avoidance of cell death. The cancer cells are able to invade into 
surrounding tissue, metastasize and finally kill the host as the result of an expansive disease 
affecting multiple organs.12 Cancer is one of the most frequent global causes of death.3 Despite 
significant research to understand the mechanism of cancer development during the last 
decades, the basic mechanism for tumour initiation and progression has not yet been fully 
understood. It is estimated that approximately 21.4 million people suffer from cancer and 
most of them will likely die of it.4 Thus, despite a lot of money and human efforts spent on 
research in the last decades, cancer still remains a major cause of death and an economic 
burden. Thus, research aimed at developing novel effective treatments is of utmost 
importance.  
1.2 Development of cancer 
The accumulation of mutations in the genes that directly control cell division or cell death 
causes the cancer, but the actual mechanism, how these mutations are generated, is still under 
debate. It has also been suggested that normal rates of mutation, together with waves of 
clonal expansion, are enough to facilitate the process in humans. Genetic modifications such 
as distinct sequence changes, invariable alterations in chromosome numbers, translocation of 
chromosomes and gene amplifications affect growth-controlling genes in neoplastic cells.5 
The well-known concept of the six hallmarks of cancer, introduced by Hanahan and 
Weinberg in 2000, contains six biological capabilities acquired during the multistep 
development of human tumours.6 During the remarkable progress in cancer research, these 
hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic 
disease that includes: 
1) The ability to sustain chronic proliferation and release of growth promoting signals;  
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2) Evading growth suppressors;  
3) Resistance to programmed cell death;  
4) Ability to form new blood vessels by angiogenesis;  
5) Enduring replicative potential;  
6) Generate secondary tumours at distant sites by metastasis as well as invasion or invasion-
metastasis cascade.6  
Recently these hallmarks were extended by the same authors to include reprogramming of 
energy metabolism as both direct and indirect consequence of oncogenic mutations and the 
ability to avoid immune destruction.7 
In general, there are two types of mutations that lead to cancer development. Oncogenic 
mutations are gain of function mutations and induce either overexpression of the gene or 
over-activation of the related protein. An oncogene may either encode for a growth factor or 
a component within a mitotic signalling cascade inside the cell. Oncogenic mutations are 
dominant, that means that only one allele needs to become mutated in order to influence 
cancer development. The second type of mutations are loss of function mutations in tumor 
suppressor genes. These genes encode for proteins that inhibit cell cycle progression or 
promote apoptosis in case of deleterious stress to the cell.8 A well-known tumour suppressor 
gene is p53, which is mutated in over 50 % of all cancers and induces apoptosis in case of 
irreparably damaged DNA.9  Both alleles of a tumour suppressor gene have to become 
mutated in order to influence cancer development, hence mutations in tumour suppressor 
genes are recessive mutations. There are two main consequences of activated oncogenes or 
inactivated tumour suppressor genes such as:  
1) the proofreading machinery that normally prevents a damaged cell from dividing is not 
working or the signalling pathways mediating programmed cell death are disrupted.  
2) the cell achieves stronger mitotic signals and divides faster. This leads to increasing 
genomic instability, additional mutations and uncontrolled development of an abnormal cell 
mass.  
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Cancer cells also release various signalling molecules with a broad range of biological effects 
on the microenvironment, including remodelling of the extracellular matrix and induction 
tumour vasculature termed angiogenesis. These effects lead to spread of tumor cells from the 
primary site to distant organs, a process which is termed metastasis. Most cancer related 
deaths result from metastatic spread. The metastatic process starts with migration of cancer 
cells from the primary site to a blood vessel, where the cells intravasate into the blood 
circulation. Cells are transported with the blood flow and eventually invade into another 
organ, a process which is still poorly understood. The whole process of metastasis depends 
on a range of factors, including the ability to evade immune destruction, altered expression 
of cell adhesion molecules, as well as activation of enzymes that break down the extracellular 
constituents that restrain cells to one place. Moreover, when the metastasizing cancer cells 
reach their final destination, the microenvironment must be permissive to sustain growth of 
the cancer cells.10 A recent review by Ribatti et al. summarizes the current knowledge on the 
spreading of certain cancers to specific organs.11 
1.3 Overview of brain cancers 
 The brain and spinal cord together form the central nervous system (CNS) which is essential 
for our existence. Cancers of the central nervous system (CNS) are classified based on their 
similarity to the main cell types of the CNS. A major portion of CNS malignancies (gliomas, 
around 81%) arise from “glia” which are the supportive tissue of the brain.12 Even though 
primary brain tumours constitute only 2% of all cancer cases,13 their dismal prognosis makes 
it an important research focus. According to the World Health Organization (WHO), primary 
brain tumors are classified as ependymoma, astrocytoma and oliogodendroglioma and.13 
Astrocytomas represent a major proportion (approximately 75%) of all gliomas. Amongst 
these, glioblastoma accounts for 55% and is the most aggressive in adults.14The WHO has 
further subclassified astrocytomas into four grades of malignancy (Grade I, II, III and IV) 
depending on specific histological criteria.13 Histological grading considers the presence of  
nuclear atypia, mitotic activity, microvascular proliferation and necroses. The classification 
of astrocytomas is summarized in table 1.  WHO Grade I pilocytic astrocytoma is a benign, 
circumscribed tumour without nuclear atypia and no visible mitotic activity and most often 
occurs in children.  It has a good prognosis and mostly requires surgical resection only. WHO 
 14
grade II-IV tumors Grade II (fibrillary astrocytoma) is characterized by moderate nuclear 
atypia and diffuse invasion into the brain parenchyma. Anaplastic astrocytomas (grade III) 
are also highly invasive and show in addition high nuclear atypia and mitotic activity. 
Glioblastoma is categorized as WHO grade IV and is differentiated from anaplastic 
astrocytoma by the presence of microvascular proliferations and necrotic areas.  The 
histological grading strongly correlates with clinical outcome.15 Low-grade gliomas are 
clinically less aggressive, and exhibit better overall survival outcome compared to high-grade 
gliomas.  
Table 1. WHO classification and grading of astrocytomas 
Grade Designation Histological feature 
I.  Pilocytic astrocytoma benign, without nuclear atypia 
II.  Astrocytoma (low-grade, diffuse) Moderate nuclear atypia  
III.  Anaplastic astrocytoma High nuclear atypia and mitotic activity 
IV.  Glioblastoma High nuclear atypia, mitotic activity, 
microvascular proliferation and necrosis 
 
1.4 Glioblastoma  
Glioblastoma (GBM) is the most frequent and most aggressive primary intracranial brain 
malignancy in adults.16, 17 GBM most likely arises from astrocytes or its precursor cells, which 
are important supportive glial cells in the brain. Patients with GBM have a poor prognosis 
with a median survival time less than 16 months.18 Percival Bailey and Harvey Cushing 
revealed the term almost a century ago due to resemblance of predominant progenitor (blast) 
cells of embryonic nervous system (Glioblastoma). The term multiforme was used to describe 
GBMs ́ characteristic intra- and inter-tumoural heterogeneity.19 
The incidence of GBM increases with age, mainly after 58 years. About 8.8% of children with 
central nervous system tumours have GBM20 and congenital cases are rare. GBM occurs more 
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often in men than woman with a ratio of 3:2 and the reason for this gender distribution is still 
unknown.21 GBM usually appear sporadically, but several genetic disorders are associated 
with increased incidence including neurofibromatosis type-1 (NF1) and type-2 (NF2), Li–
Fraumeni syndrome (LFS), Von Hippel Lindau disease (VHL),21 tuberous sclerosis, Turcot 
syndrome and multiple endocrine neoplasia type IIA. In addition, acquired head injuries, 
which occurred as a result of a brain contusion, may predispose to the onset of glioblastoma.22, 
23  
It was believed that viruses, such as human cytomegalovirus (HCMV), causes glioma 
development and stimulates congenital encephalitis and multi-organ changes in adults. 
Human cytomegalovirus displays tropism for glial cells. Since the viral genes encode proteins 
(e.g. IE1, US28, GB), they activate intracellular signalling pathways involved in mitogenesis, 
mutagenesis, apoptosis, inflammation and angiogenesis. Thus, products of these genes cause 
disruption of the key signalling pathways (including PDGFR, Akt, STAT3), but also cause 
troubles in monocyte and glial cell functions.24, 25 
Ionizing radiation is one of causes for developing this type of tumour. Chemicals like 
pesticides, polycyclic aromatic compounds and solvents are also considered as potentially 
dangerous. At the same time, electromagnetic  fields and certain metals cause glioma 
development.26 Although the use of a mobile phone does not increase the risk of developing 
glioblastoma, the long-term effect for using of mobile phones is still not clear. Moreover, 
working peoples in the rubber and petrochemical industry have higher risk for glioma 
development. Thus, glioblastoma is considered as an occupational disease.27, 28 
GBM cells generally show rapid cell proliferation and induce pathologic tumor 
vascularization which produces tumour areas with insufficient oxygen supply.29 This chronic 
exposure to extremely low levels of oxygen frequently produces necrotic zones surrounded 
by densely packed hypoxic tumour cells. These so-called pseudo-palisading GBM cells were 
shown to express hypoxia-regulated genes that control crucial processes associated with 
tumour aggressiveness such as angiogenesis, extracellular matrix degradation, and invasive 
behaviour.30, 31 Hypoxia is also a well-recognized component of the tumour 
microenvironment and has been linked to poor patient outcome and resistance to therapies 
in different cancer types.32 
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1.4.1 Classification of GBM 
GBM is classified as either primary or secondary in origin. Primary GBM (de novo) arises 
from normal glial cells or its progenitor cells in around 90% of diagnosed GBM cases without 
prior evidence of less malignant lesions. The remaining 10% GBM cases are secondary lesions 
originating from low‐grade or anaplastic astrocytoma. The transformation process from low 
grade to high grade astrocytoma and secondary GBM mostly takes several years.33-35 
Primary and secondary GBM show no morphological differences. However, the genetic basis, 
as well as the molecular pathways involved in the development of primary and secondary 
GBMs are different (Fig. 1). Primary GBM are characterized by LOH chromosome 10q (69%), 
a high frequency of EGFR amplification (45%), p16 INK4a deletion, MDM2 amplification and 
loss of PTEN (24–34%). In contrast, secondary GBMs are characterized by IDH1 and P53 
mutations, RB gene alterations, and amplification and/or overexpression of the PDGFR 
gene.36 Common to both primary and secondary glioblastoma is LOH on 10q, which is distal 
to the PTEN locus. Of the TP53 point mutations in secondary glioblastomas, 57% are located 
in hotspot codons 248 and 273, while in primary glioblastomas, mutations are more widely 
distributed.33 These genetic changes together with differences in the transcriptome define  
molecular subclasses of GBM which are  mesenchymal, classical and proneural.37, 38 
 
 
Fig. 1 Genetic alterations in primary and secondary glioma. (taken from39) 
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1.4.2 Symptoms and diagnosis 
Common clinical symptoms are dysphagia, seizures, headaches, cognitive changes, vision 
disturbance (blurred vision, diplopia), vomiting, ataxia, dizziness, and frequent syncopes.40, 
41 Due to these unspecific symptoms, gliomas can be misdiagnosed and therefore radiology 
is an important step in the diagnostic process.42 Gliomas most frequently arise in the frontal 
lobes (40%), while temporal and parietal lobes account for 29% and 14% of cases, 
respectively.43 Progression of high intracranial pressure is one of the most dangerous features 
of GBM.40  
Imaging techniques such as magnetic resonance imaging or computer tomography is the 
primary diagnostic tool for GBM. Post contrast T1 weighted spin echo MRI images show 
irregular hypo-intense signal with ring like enhancement at the tumour margin which 
indicates disruption of blood brain barrier (BBB) in GBM.44 This is also an indicator of neo-
angiogenesis, the process whereby new vessels are formed by sprouting from pre-existing 
blood vessels. T2 diffusion weighted MRI is useful for evaluation of peri-tumour oedema that 
appears as a hyper-intense signal (Fig. 2). Cerebral abscess, vascular infarction, lymphoma or 
metastases from distant organ sites can mimic glioblastoma on neuroimaging, thus the final 
diagnosis is determined by histology.  
 
Fig. 2 Magnetic resonance imaging of Glioblastoma. GBM in right parietal lobe a) Post contrast T1-weighted image 
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shows irregular ring shaped enhanced signal b) T2 weighted image shows high signal intensity with oedema 
surrounding tumour. (taken from 44 ) 
1.4.3 Macroscopic features 
Macroscopically, GBM lesions vary in size, usually 5-10 cm in diameter in most of the cases.27 
Lesions usually present as intraparenchymal round masses where the borders between 
normal and pathological tissue are poorly demarcated (Fig. 3). Peritumoural oedema with 
mass effect contributes to shift of midline structures. Concurrent haemorrhage and or 
necrosis give a variegated appearance of the tumour. Tumours are mostly solitary, but can 
spread to the contralateral hemisphere and give rise to butterfly-like lesion. Uneven 
distribution and poor margin of the tumour is a huge obstacle for GBM surgery. Maximal 




Fig. 3 Gross morphology of Glioblastoma. Coronal section of a Glioblastoma showing-  a) irregular margin b) 
necrosis c) midline shifting d) contralateral hemorrhage. (taken from 
http://library.med.utah.edu/WebPath/CNSHTML/CNS136.html) 
1.4.4 Microscopic feature 
GBMs are hypercellular and extremely mitotically active tumors. This ends up in an extreme 
unmet demand for oxygenation and metabolism resulting in hypoxia and tissue necrosis. 
GBM has an important feature called Necrotic foci. There are two types of necrosis depending 
on the size and position of the necrotic area. First type has large areas of necrosis within the 
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main area of the tumour. This type appears due to inadequate blood supply in all primary 
glioblastomas. The other type can easily be detected by tiny, unevenly shaped necrotic foci 
encircled by pseudopalisading zone. This type appears in both primary and secondary 
glioblastomas (Fig. 4).45 Pseudopalisades are typically 30 - 1500 μm in the  internal width and 
50 - 3500 μm in the  internal length.31 
Hypoxia in turn upregulates hypoxia-inducible factor 1-alpha (HIF-1α) leading to increased 
vascular endothelial growth factor (VEGF) secretion that induces sprouting of new blood 
vessels from the pre-existing through angiogenesis. GBM is thus highly vascularized by 
unique microvessels forming glomeruloid tufts lacking lumen and BBB. These microvascular 
proliferations are leaky and contribute to the development of edema. Moreover, the tumour 




Fig. 4 Histological H&E staining of GBM showing a) Glomerular pattern of angiogenesis (microvascular 
proliferation), b) central area of necrosis c) arrangement of tumour cells surrounding necrosis-pseudopalisading 
necrosis. Magnification 100X, scale bar = 100 μm. (taken from 45) 
1.5 Hypoxia and the role of hypoxia-inducible factors in GBM 
In addition to the features described above, GBM show a high degree of infiltration of diverse 
immune cells, including microglia, macrophages, and lymphocytes.46, 47 This composition 
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cells generate a GBM-specific tumour microenvironment (TME), which plays a crucial role in 
tumour progression, immune escape, local invasion and distant invasion of GBM.48, 49 The 
tumour and its surrounding microenvironment are closely related and interact constantly.50 
During the stages of tumour progression, a hypoxic TME or pro-oxidant-enriched TME is 
formed; these TMEs have both beneficial and harmful effects on tumour cells and their niche. 
The TME is characterized by low levels of glucose and amino acids, acidosis, and hypoxia.51  
A Hypoxic state arises in glioblastomas because of uncontrolled cell proliferation, erratic 
tumour neovascularization, poor oxygen diffusion, disruption of the blood-brain barrier, 
poor permeability of nitric oxide and intra-tumoral necrosis that interferes with oxygen 
perfusion (Fig. 5).52 Tumour hypoxia is associated with metastases,53 recurrences54 and 
resistance to chemotherapy and radiation therapy.55 These effects are mediated by a family 
of transcription factors called hypoxia-inducible factors (HIF-1α and HIF-2α).56 HIF-1α 
expression and activity is highly dependent on oxygen supply; under normoxic conditions, 
HIF-1α is rapidly hydroxylated by prolyl hydroxylase domain (PHD)-containing proteins 
and subsequently polyubiquitinated by the von Hippel–Lindau tumour suppressor (pVHL) 
for degradation through the proteasome pathway.56 Under hypoxic conditions, pVHL-
mediated HIF-1α degradation is abolished, causing HIF-1α to accumulate and translocate to 
the nucleus where it forms a heterodimer with HIF-1β, which can bind to hypoxia responsive 
elements (HREs) in the promoters of hypoxia-regulated genes.57, 58  
Furthermore, hypoxic areas detected in GBM can correlate with poorer outcomes and greater 
proliferation of CSCs, which may drive tumour resistance and recurrence, as well as 
regulation of the tumour microenvironment.52 
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Fig. 5 Regulation of hypoxia signalling in glioblastoma. Hypoxia-inducible factor (HIF) signalling during 
normoxia and hypoxia as well as the interaction between HIFs and epithelial-mesenchymal transition are 
represented in glioblastoma. (A) During normoxia, increased activity of prolyl hydroxylase domain (PHD)-
containing protein level that results in hydroxylation of HIF-1 residues (P-564, P-402), which recruits the von 
Hippel-Lindau (VHL) complex. (B) During hypoxia (1%-2% O2), HIF-1 remains unhydroxylated, resulting in 
recruitment of HIF-1/aryl hydrocarbon receptor nuclear translocator (ARNT) and the coactivator CBP/p300, 
which bind to hypoxia response elements (HRE) involving expression of several hundred downstream 
transcription factors, including those involved in mesenchymal transformation. HIF-1 can also be upregulated 
by various downstream regulators from receptor tyrosine kinases (e.g., PI3K/AKT/mTOR, Ras/Raf/MAPK). Cul2, 
cullin 2; MAPK, mitogen-activated protein kinase; MEK1/2, MAPK kinase; mTOR, mammalian target of 
rapamycin; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; Rbx1, ring-box 1, E3 ubiquitin protein ligase; 
RTK, receptor tyrosine kinase. (taken from 59) 
An important downstream activation of HIF signalling cascade is angiogenesis. Not 
surprisingly, a histologic hallmark of glioblastoma is microvascular proliferation. Despite the 
apparent abundance of angiogenic activity, a characteristic feature of glioblastoma is 
abnormally functioning blood vessels. Vessels lack the structural support of pericytes and are 
characteristically tortuous and leaky, impeding blood flow and decreasing perfusion.60 At the 
tumour tissue level, microvascular thromboses occlude vessels, further promoting 
intratumoral hypoxia.60 Because the volume of blood flow influences regional tissue 
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oxygenation, understanding the crosstalk between GSCs and the neighbouring blood vessels 
may provide novel therapeutic opportunities. 
1.6. Epithelial-mesenchymal transition (EMT) 
Epithelial-mesenchymal transition (EMT) is a reversible biological process in which polarized 
epithelial cells are induced to undergo numerous biochemical changes including loss of 
epithelial cell polarity, loss of cell-cell contacts, and increased motility that results in a 
mesenchymal phenotype, characterized by an enhanced migratory capacity and elevated 
resistance to genotoxic agents (Fig. 6). Additionally, EMT is a vital inducer of the cancer stem 
cell phenotype. GBM is not an epitehelial cancer, however, an EMT-like process has been 
described for GBM. On this point, the mesenchymal subtype of glioblastoma (GBM) is 
associated with a destructive phenotype.  The existence of a CSC population has also been 
proven in malignant gliomas, however, the co-existence of a stem cell status with EMT(-like) 
processes in GBMs has been described only recently.61, 62 
The microenvironment that induces EMT in gliomas is characterized by hypoxia and the 
enrichment of myeloid cells following stimulation by transforming growth factor-β (TGF- β), 
epidermal growth factor, platelet‐derived growth factor and fibroblast growth factor‐2 and 
also numerous proteases that increase invasiveness into the surrounding normal brain.63 
 
Fig. 6 Scheme for the epithelial-mesenchymal transition in glioma cells. (taken from 63) 
1.7 Formation of Caveolae, Cavins, Caveolin-1 and its versatility 
Caveolae are plasma membrane subdomains of distinct lipid and protein compositions 
present in many mammalian cells. These submicroscopic, flask-shaped invaginations, occupy 
up to 20% of the plasma membrane which play multiple roles in cell physiology, including 
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signalling platforms for numerous pathways, clathrin-independent routes of endocytosis, 
lipid homeostasis, tumorigenesis, mechano-transduction and mechanical stress sensors.64, 65 
The formation of cholesterol-rich, small Ω- shaped caveolae require a protein family called 
caveolins, in which caveolin-1, best known as a membrane integral protein, is a key 
component of caveole structure. Caveolae were first morphologically identified in 1950s by 
transmission electron microscopy and were described as structures resembling `little caves' 
due to their appearance as 50- to 100-nm vesicular invaginations of the plasma membrane 
and Cav-1 or VIP21 was first identified in Rous sarcoma transfected cells and found to be a 
substrate of v-Src and trans-Golgi derived transport vesicles. Since then, three isoforms of the 
caveolin family, caveolin-1, -2, and -3 have been identified and all of them are sufficient for 
caveolae formation in most tissues and striated muscle, respectively. Cav-2 associates with 
Cav-1 in hetero-oligomers and does not independently form caveolae.66 Additionally  caveole 
formation and functions are known to involve a family of cytoplasmic proteins named cavins.  
Cavin-1 (polymerase I) and transcript release factor (PTRF), are only essential for caveolae 
formation. Additionally, it involves in transcription termination via interaction with RNA 
polymerase and in regulation of type I collagen gene expression by interacting with a DNA-
binding transcription factor.67, 68 
Caveolae are thought to function as signalling platforms regulating the activation of several 
signaling pathways such as many receptor and non-receptor tyrosine kinases,  hepatocyte 
growth factor (HGF) receptor, platelet- derived growth factor receptor (PDGFR), epidermal 
growth factor receptor (EGFR), endothelial nitric oxide synthase (eNOS), proteins involved 
in calcium transport, H-Ras, integrins, nerve growth factor, serine/threonine kinases, 
phospholipases, G protein-coupled receptors and Src family kinases. Cav-1 binds and 
tonically inhibits the activation of such signalling platforms which facilitate the signaling 
cascades that contribute to cancer regulation. As a consequence, many studies recognize Cav-
1 as a modulator of cell transformation, proliferation and metastasis.69 
Cav-1 is well known principle scaffolding protein of caveole that directly interacts with 
several signalling molecules (growth factor receptors, kinases, G- proteins and adhesion 
molecules) in caveolae to control their subcellular distribution and activation status70, 71 
Human Cav-1 belongs to a highly conserved gene family, composed of three exons and 
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alternatively translated into the endoplasmatic reticulum (ER) as a full-length 178 amino 
acids alpha-isoform and a beta-isoform truncated by the first 32 amino acids at the N-
terminus which is derived from an alternative translation start72 (Fig. 7A) and is co-expressed 
with caveolin-2 in cells and tissues of mesenchymal, endo/epithelial, neuronal/ glial origin.73 
Cav-1 is believed to have a membrane spanning unique hairpin conformation where both C- 
and N-termini are exposed to the cytosol (Fig. 7B).  
 
Fig. 7 Schematic structure of Cav-1 gene and protein.74 
Cav-1, via its scaffolding domain (CSD) (amino acids 82–101) interacts with a variety of 
specific partner proteins binds short peptide motifs that rich in aromatic residues such as 
x4x2 ( = aromatic acid, x = any amino acid).75 Other important domains include an 
oligomerization domain (amino acids 61–101) of Cav-1 monomers assemble into high-
molecular weight homo- and hetero-oligomers (with caveolin-2) to form the striated caveolar 
coat structure (Fig. 8).  
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Fig. 8 Caveolin oligomer formation is regulated due to interaction with cavin members. Cav-1 and cav-2 can exist 
as monomers, homodimers, or heterodimers. The presence of both Cavin-1 and Cavin-2 allows Cav-1 or Cav-2 to 
interact within the cell membrane to form hetero-oligomers in caveolae. In the absence of Cavin-1 or Cavin-2, 
caveolin oligomers embedded in the cell membrane cannot contribute to caveolae formation. (taken from 76) 
1.8 Role of Cav-1 in cancer progression and in GBM 
Over the past 10-15 years, Cav-1 has been found to have oncogenic and metastasis promoting 
roles, however, others have described opposing roles of being either a tumour suppressor or 
an oncogene depending on the tumour type or tissue of interest.77-79 Down-regulation of Cav-
1 expression is observed previously in breast, colon, lung and ovarian cancer. Thus, 
oncogenic transformation of cells was associated with reduction of Cav-1 expression, and 
antisense-mediated down-regulation of Cav-1 expression was sufficient to drive oncogenic 
transformation in NIH 3T3 cells. Moreover, exogenous expression of Cav-1 in oncogenically 
transformed cells and cancer cell lines inhibited cell growth and tumorigenesis. This evidence 
indicates that Cav-1 can act as a tumour suppressor. In contrast, other studies have reported 
that Cav-1 expression was up-regulated in human cancers in association with metastases and 
poor prognosis. These results suggest that Cav-1 can function as an tumour promoter as 
well.80 The tumour-promoting role of Cav-1 in metastasis is assumed to be based on its 
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general role in enabling and supporting membrane viscosity/fluidity and cell motility.81 Cav-
1 has been validated as a participating protein that is targeted to zonula adherens (Adherens 
junction, ZA) and zonula occludens (Tight junction, TJ), to stabilize them in order to maintain 
epithelial82, 83 and endothelial barriers in vitro84 and in vivo (e.g. blood–brain-barrier13). 
Metastasis involves a loosening of both cell–cell and cell–matrix contacts and degradation of 
the extracellular matrix (ECM) to promote cell motility and invasion. In addition Cav-1 seems 
to play a role in the angiogenic process, as confirmed by knock-down of Cav-1 expression by 
antisense oligonucleotides85 or RNAi-based approaches86, resulting in blockage of 
angiogenesis.  
Interestingly, one of the most frequent point mutants in GBM occurs in the tumour 
suppressor protein, p53.87 in certain p53- mutant tumours, glucose restriction, which induces 
oxidative stress, resulted in activation of autophagy and an autophagy-dependent 
degradation of mutant p53, leading to a feed forward acceleration of autophagy and tumour 
inhibition.88 Furthermore, in the tumour stroma, Cav-1 expression has been found to be 
similarly downregulated by oxidative stress when autophagy was activated, which, in turn, 
resulted in a feedforward upregulation of stromal autophagy.89 Termed the “reverse 
Warburg effect,” this tumour microenvironment is defined by enhanced stromal aerobic 
glycolysis, oxidative stress and localized inflammation, which, in turn, promotes tumour cell 
survival through cancer cell parasitism of nutrients released from the autophagic stromal 
cells. Collectively, these results suggest that the expression levels of Cav-1, and certain 
mutant forms of p53, may be regulated in a similar fashion by autophagy, leading, however, 
to different phenotypic outcomes depending upon whether their expression occurs in the 
tumour or in the stromal component.88-90 
The most commonly silenced genes TP53 and the tumour suppressor proteins PTEN in GBM 
involve antagonizing the PI3K/AKT/mTOR pathway and regulate cell cycle, which react to 
DNA damage and cell death, respectively. Notably, these two genes are highly upregulated 
in cells overexpressing Cav-1. This explains the gene signatures connected to downregulation 
of signalling pathways as well as reduced invasiveness.91 
Cellular senescence is a powerful tumor suppressor mechanism. In the literature, it was 
shown that Cav-1 promoted stress-induced premature senescence in fibroblasts through the 
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modulation of Mdm2, ATM, PP2A-C, Nrf2, and Sirt1 functions. Thus, it remains unexplored 
whether Cav-1 regulates the tumor suppressor properties of oncogene-induced senescence. 
Around two decades ago, it was shown that overexpression of oncogenic H-Ras (H-RasG12V) 
in normal cells was enough to induce cellular senescence instead of increasing cell 
proliferation. Studies have demonstrated that senescence happens in premalignant lesions in 
several mouse cancer models, including lymphoma, prostate, mammary and lung carcinoma. 
Additionally, senescence was found in benign lesions of the prostate, skin and neurofibromas 
in human and was associated with oncogenic mutation of BRAF, PTEN inactivation and NF1 
mutations. In this way, cellular senescence is activated by the same oncogene that leads the 
initial tumorigenesis to progress the cancer.92 
Genetic evidence emerging from gene mapping studies revealed that the human Cav-1 gene 
maps to the long arm of human chromosome 7 (7q31.1). This region, the D7S522 locus, 
encompasses a known fragile site (FRA7G) and is often associated with loss of het- 
erozygosity (LOH) in various cancers. The deletion of this region and its association with the 
pathogenesis of several different types of cancers lends credible support to the presence of a 
tumor suppressor gene within this genetic locus. While no genes have been directly mapped 
to the D7S522 locus, the closest genes to this region encode caveolin-2 and Cav-1.93-95 
Overexpression of Cav-1 in cultured cells is sufficient to inhibit signalling from several 
proliferative pathways. For instance, it has been shown that key components of the Ras-
p42/44 MAP kinase cascade (MEK and ERK) reside within caveolae and other members of 
this signaling cascade are negatively regulated by a direct interaction with Cav-1. It has also 
been demonstrated that transient transfection of Cav-1 dramatically inhibits signalling along 
the Raf-1/MEK/ERK pathway, and the kinase activity of MEK-1 and ERK-2 are inhibited by 




Fig. 9 Schematic diagram of various role of Cav-1. Red lines denote genes or pathways inhibited by Cav-1, while 
green lines indicate those that are upregulated.97 
In recent publication, Talasia et al. performed the human gene v1.0 ST microarray on 
xenograft tissues. They harvested tumors until those reached similar sizes by observing with 
MRI. At the same time, tissues containing >90% tumors were harvested for RNA isolation. 
Microarray analysis revealed six hundred forty-five genes differentially expressed between 
the phenotypes. Among them top 30 genes mostly deregulated between the two groups were 
also isolated (Fig. 10).98 The analysis of associations of gene expression with biological 
functions, revealed that the genes upregulated in the angiogenic xenografts indeed are 
involved in angiogenesis, response to wounding, and response to cellular stress. In the gene 
expression data, they also showed that Cav-1 is one of the top genes among other genes that 
upregulated in the mesenchymal subtypes. Thus, it is still unclear whether Cav-1 is a tumor 
suppressor or promotor in GBM. 
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Fig. 10 The gene expression data show that the angiogenic switch is linked to proneural-to-mesenchymal 
transition in GBM (taken from98 ). Shown are the highest differentially expressed genes between invasive EGFR 
amplified cells and tumors transduced with EGFR-DN resulting in angiogenic tumours of the mesenchymal 
subtype. Among 30 genes, Cav-1 is one of the top genes that is upregulated in the mesenchymal subtype. 
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2. Aims 
We aim to develop this project by adopting the following strategy: 
1. Analyse TCGA data for correlation/anticorrelation of mesenchymal/proneural 
markers with Cav-1 
2. Analyse expression patterns of Cav-1 in GBM patient samples 
3. Analyse HIF-1α expression under normoxia and hypoxia in patient-derived primary 
GBM cell lines 
4. Test the efficacy of digoxin to block HIF-1α upregulation under hypoxia 
5. Evaluate Cav-1 expression under normoxic and hypoxic conditions in patient-derived 
primary GBM cell lines by western blotting 
6. Analyse expression of proneural and mesenchymal markers under normoxia and 
hypoxia by western blotting. 
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3. Materials and Methods 
The project was conducted from August 2017 to May 2018 at the Department of Biomedicine, 
University of Bergen, Norway. 
3.1 List of materials 
Table 2: Experimental cell lines 
Cell line Type Supplier 
BG5 GBM Haukeland Hospital, Bergen, Norway 
BG7 GBM Haukeland Hospital, Bergen, Norway 
GG14 GBM University Medical Center Groningen, 
Netherlands 
GG16 GBM University Medical Center Groningen, 
Netherlands 
S24 GBM German Cancer Research Center (DKFZ), 
Heidelberg 
Each experimental cell lines were cultured in two micro-environmental conditions - 
normoxia and hypoxia. 
Table 3: General chemicals and solutions 
Chemical/solutions Catalogue no. Supplier 
Methanol (100%) 1060092500 Sigma-Aldrich, St. Louis, Missouri, 
USA 
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Ponceau P3504 Sigma-Aldrich, St. Louis, Missouri, 
USA 
Soduim cloride (NaCl) S0390 Sigma-Aldrich, St. Louis, Missouri, 
USA 
Ethanol, absolute 32221 Sigma-Aldrich, St. Louis, Missouri, 
USA 
Dulbecco’s Phosphate 
Buffered Saline (10x) (PBS) 
D1408 Sigma-Aldrich, St. Louis, Missouri, 
USA 
Accutase A6964 Sigma-Aldrich, St. Louis, Missouri, 
USA 
Neurobasal medium(NBM) 21103-049 Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA 
bFGF (Fibroblast Growth 
Factor-basic) 
100-18B Peprotech, Germany 
B27 17504-044 Thermo Fisher Scientific, Waltham, 
MA, USA 
EGF (Epidermal Growth 
Factor) 
236-EG-200 R & D System 
Virkon tablets for 
decontamination 
VIRKTABS Wilmington, Delaware, USA 
 
Table 4: Reagents for western blotting 
Reagents Catalogue number Supplier 
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M-PER Mammalian Protein 
Extraction Reagent kit 
78503 Thermo Fisher Scientific, 
Waltham, MA, USA 
Protease and Phosphatase Inhibitor 
Cocktail(100X) 
78440 Thermo Fisher Scientific, 
Waltham, MA, USA 
NuPAGE® TM Antioxidant NP0005 Invitrogen by Thermo Fisher 
Scientific 
NuPAGE® TM 4-12% Bis-Tris Gel (15 
wells) 
NP0323 Invitrogen by Thermo Fisher 
Scientific 
NuPAGE® ® (4-12% gradient Bis-
Tris gels (10wells) 
NP0321 Invitrogen by Thermo Fisher 
Scientific 
NuPAGE® Sample Reducing agent 
(10X) 
NP0004 Invitrogen, Carlsbad, 
California, USA 
SeeBlue® Plus2 Prestained Standard 
(1X) 
LC5925 Invitrogen, Carlsbad, 
California, USA 
NuPAGE® LDS sample buffer (4X) NP0007 Invitrogen, Carlsbad, 
California, USA 
NuPAGE® MOPS SDS Running 
buffer (20X) 
NP0001 Novex by Life Technoogies 
NuPAGE® Transfer buffer (20X) NP0006-1 Novex by Life Technoogies 
Super Signal® West Femto 34096 TFS 
Super Signal® West Pico 34080 TFS 
Triton TM X-100 9002-93-1 Sigma-Aldrich, St. Louis, 
Missouri, USA 
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Tween 20 9005-64-5 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Tris Base 648310 Merck Chemicals, 
Darmstadt, Germany 
Nitrocellulose transfer membrane 
(0.2 m) 
10600001 GE Healthcare, Pittsburgh, 
PA, USA 
DifcoTM Skim milk powder 232100 BD Biosciences, Franklin 
Lakes, NJ, USA 
Bovine serum albumin (BSA) A4503 Sigma-Aldrich, St. Louis, 
Missouri, USA 
 
Table 5: Reagents for immunostaining 
Reagents Catalogue no. Supplier 
Prolong Gold antifade reagent with DAPI P36935 Molecular probes, USA 
Corning® Matrigel® Matrix Growth Factor 
Reduced (GFR) Basement Membrane 
Matrix 
 
356230 Corning Incorporated Life 
Sciences, Tewksbury, MA 
01876 
Normal goat serum (1:50) - Dako Denmark A/S, 
Glostrup, Denmark 
 







HIF1A 51608 1:500 PBS + BSA Abcam 
 
Table 7: Secondary antibody for immunostaining 
Name Catalogue 
no. 
Dilution  Dilution buffer supplier 
Goat anti-mouse 
Alexa 488 (green) 
A10235 1:200 PBS + BSA Thermo Fisher Scientific, 
Waltham, MA, USA 
 
Table 8: Inhibitor for immunostaining 
Name CAS No. Supplier 
Digoxin 20830-75-5 Axon Medchem 
 
Table 9: Primary antibody for WB 
Source of the primary antibody is rabbit for all except, Anti EZH2 and Anti HI1-A (both of 












31645 1:1000 195 Milk Cell signalling 
Technology, 
USA 
Anti-PSTAT3 9134p 1:1000 86 BSA Cell signalling 
Technology, 
USA 
Anti-EZH2 3147 1:1000 98 Milk Cell signalling 
Technology, 
USA 
Anti-YKL40 30465 1:500 40 Milk Santa Cruz 
Biotechnology 
Anti-HIF1A 51608 1:1000 120 Milk Abcam 
Anti-Cav1 2910 1:1000 21,24 Milk Abcam 
Anti-Olig2 9610 1:5000 32 Milk EMD Millipore 
Anti-BMI 05-637 1:1000 37 BSA EMD Millipore 
Anti-CD44 7923 1:2000 82 Milk Sigma Aldrich 
Anti-HIF1A 610959 1:250 120 Milk BD Translab 
Anti-GAPDH 9485 1:5000 37 BSA Abcam 
 
Table 10: Secondary Antibodies for WB 
All the secondary antibodies were supplied by Thermo Fisher scientific, Waltham, MA, USA 
except anti-goat IgG-B, which is from Santa Cruz Biotechnology, INC 
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Name Catalogue No. Animal of origin Dilution Blocking buffer 
Anti-rabbit HRP 31462 Goat 1:10,000 BSA/Milk 
Anti-goat IgG-B 2042 Donkey 1:5000 BSA 
Anti-mouse HRP 31430 Mouse  BSA/Milk 
 
Table 11: Equipment for all experiment  
Equipment Supplier 
Power Pac 300 electrophoresis power 
supply 
164-5050 Bio-Rad, Hercules, CA, USA  
Nikon E100 Light microscope Nikon Instruments, Tokyo, Japan 
Fluorescence microscope  3512000236, Zeiss AXIOZ1, Germany 
Holten laminar airflow clean benches SANYO Electric Co, Osaka, Japan) 
Luminescent Image Analyzer LAS (3000) 
Fujifilm UV intelligent dark box 
4622724, Fujifilm Medical Systems Inc., 
Stamford, CT, USA 
Cell culture CO2 incubator Panasonic Healthcare Co. Ltd. Sakata, Japan 
Hypoxia C-chamber Panasonic Healthcare Co. Ltd. Sakata, Japan 
Inverted Microscope TS100/TS100F, Biocompare, USA 
Eppendorf centrifuge 5424 R Eppendorf, Hamburg, Germany  
Versa Max Microplate Reader Molecular devices, Sunnyvale, CA, USA 
Direct Detector™ Spectrometer DDHW00010-WW, Merck Millipore, USA 
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Trans-Blot Turbo™ Transfer System Bio-Rad, Hercules, CA, USA 
SH800Z Cell Sorter  Sony Biotechnology, Japan 
Automated cell counter NucleoCounter® 
NC-200™ 
ChemoMetec A/S, Denmark 
SimpliAmp Thermal Cycler Thermo Fisher Scientific, Waltham, MA USA  
Cellular RNA detection, Bioanalyzer 
System  
2100, Agilent Technologies, Waldbronn, 
Germany 
Heraeus Multifuge 3SR Plus Centrifuge DJB Labcare, Thermo Fisher Scientific, UK 
 
3.2 Recipes for used buffers 
Neurobasal Medium (NBM): NBM is supplemented with B27, L-Glutamax, penicillin- 
streptomycin, heparin, 20ng/ml bFGF (Fibroblast Growth Factor-basic) and 20ng/ml EGF 
(Epidermal Growth Factor),  
Phosphate buffered Saline (PBS): Dulbecco’s Phosphate Buffered saline (PBS, 10x) is diluted 
at a concentration of 10% v/v volume of in 9 volumes of autoclaved Milli-Q water. 
Cell-freezing medium: 10% v/v DMSO and 20% v/v heat inactivated foetal bovine serum 
(FBS) were added to DMEM. 
4 % v/v Para formaldehyde (PFA) solution: Fixation reagent was prepared by adding 1 
volume of 16%v/v PFA solution in 3 volumes of 1x PBS. 
Ponceau S: 0.1% w/v Ponceau stain was added in 5 % v/v acetic acid 
SDS-PAGE running buffer: 50 ml of 20X MOPS was diluted with 950 ml of Milli-Q water 
and 500 μl NuPAGE® antioxidant. 
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Transfer buffer: 50ml of 20% NuPAGE® transfer buffer, 100ml of methanol, 1ml of 
NuPAGE® antioxidant were mixed to 849ml of milli-Q water. 
Western blot wash buffers: For 1 litre (TBS) 10x: 20 Mm Tris-HCL, 0.15 M NaCl is mixed in 
900ml of Milli- Q followed by adjustment of pH at 7.6. 
TBST (1%): 100 ml TBS(10X) is mixed with 900ml milli-Q water and 1ml Tween. 
Western blot blocking buffer: 5% w/v skim milk powder TBST and 5% w/v BSA TBST. 
3.3 Methods 
3.3.1 Cell culture 
Fresh Human Glioblastoma samples were processed for cell cultures within 1 hour after 
reception. As reference material for all experiments, the glioblastoma cells (GBM) were 
routinely cultured as neurosphere in 75 cm2 culture flasks (Nunc, Thermo Fischer Scientific, 
Waltham, Massachusetts, USA) in Neurobasal medium, supplemented with necessary 
ingredients as described in section 3.2. Glioblastoma cell lines were kept at 37 0C in tissue 
culture incubators at 100 % humidity with 5 % CO2 and 95 % air. For hypoxia treatment, cells 
were first maintained in the regular normoxic incubator for around 12 hours. The idea of 
giving some time following disccociation of the spheroids is to let them overcome the stress 
caused by accutase and mechanical dissociations by repeated pipetting. Therafter the flasks 
were transferred to the Hypoxia C-chamber, (Panasonic Healthcare Co. Ltd. Sakata, Japan) 
filled with 1% O2, 5% CO2 and 94% N2, at 98% humidity and 37 °C. 
3.3.2 Passaging 
The cells were cultured generally at 70-90% confluency and passaged almost once a week to 
avoid overgrowth. Old medium was removed by centrifugation at 400 rpm for 5 minutes and 
cells were washed twice with 1x phosphate buffered saline (PBS). Neurospheres were 
dissociated by incubation at 37 OC in Accutase (Cat. No A6964, Sigma Aldrich) for around 3-
5 minutes. Accutase was inactivated by adding supplemented Neurobasal Medium (NBM), 
(Gibco, Cat. No. 211103-049). Supernatant were discarded and 15 ml of fresh NB medium was 
added. The cell suspension was gently pipetted up and down to dissociate the spheroids and 
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produce a solution of single and rounded cells under the microscope. Passage number, 
owner’s name and date were registered each time the cells were passaged. Passaging of cells 
was carried out in a laminar flow bench (SANYO Electric Co, Osaka, Japan) that was 
sterilized with 70 % ethanol before and after use. Cells were visualized using an inverted 
light microscope.  
3.3.3 Cryopreservation of cells 
Cells were frozen down for cryopreservation after 4 passages. Cells were gently detached 
and a single cell suspension was made. Then, the cell suspension was transferred to a 15ml 
centrifuge tube and centrifuged at 900rpm for 5 minutes. After discarding the supernatant, 
pelleted cells were re-suspended in RT (10% v/v DMSO, 10% v/v foetal bovine serum 
complete medium). The cells were homogenously mixed and transferred to cryovials. Cryo-
vials were marked with name of the cell line, passage number, date, and name of owner and 
placed in an isopropanol containing box at room temperature. Cells in isopropanol box were 
stored at –80°C for overnight. Frozen cells were then transferred to the liquid nitrogen tank 
for long-term storage. 
3.3.4 Thawing of cells 
Cells were collected from the N2 tank, and transported in ice box and thawed by placing the 
cryotubes in a 37 OC water bath gently. Immediately after thawing, the cell suspension was 
transferred to a 15ml tube and washed with 5ml of PBS and centrifuged at 900 rpm for 5 
minutes. After discarding the supernatant, pelleted cells were re-suspended in 6-7 ml of 
NBM. After 24 hours incubation at 37 OC, the medium was changed to remove remnants of 
freezing solution which may otherwise harm the cells.  
3.3.5 Cell counting 
Cells were rinsed with 5 ml of 1x PBS and treated with 1ml of accutase. The flask was 
incubated for 3-5 minutes in the incubator (37 OC and 5% CO2) according to the size of the 
cell pellet. Approximately 10 ml of NBM was added in the culture flask, pipetted up and 
down gently and then the suspension was filled into a falcon tube. 100 μl cell suspension was 
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transferred into an eppendorf tube for cell counting by Automated cell counter 
NucleoCounter® NC-200™. 
3.3.6 SDS-PAGE and western blotting 
Western blotting is a widely used technique for identification of specific proteins from the 
complex mixture of proteins extracted from cells. Protein is separated by SDS-PAGE (sodium 
dodecyl sulfate polyacrylamide gel electrophoresis) based on their molecular weight, size 
and ability to bind to specific antibodies. 
Later, Proteins are transferred to a nitrocellulose membrane producing a band for each 
protein followed by incubation with epitope specific primary and secondary antibodies that 
binds to the particular proteins on the membrane. The unbound antibody is washed off 
leaving only the bound antibody to the protein of interest. Finally, the bound antibodies are 
then detected by the image, which is processed by chemiluminescent agent and visualized 
by a luminescent image analyser. 
Immunoblotting is a semi quantitative technique that provides a relative comparison of 
protein levels rather than absolute measure of quantity. Housekeeping protein GAPDH are 
used as loading control.  
3.3.7 Isolation of protein 
Old media was removed which was transferred to the 15ml tube and cells were washed twice 
with 10-12 ml of ice-cold 1x phosphate buffered saline (1xPBS) followed by centrifuged at 
3000 rpm for 3-4 minutes in 2 0C. According to the method, 150-200μl protein lysis buffer (M-
PER with Protease and phosphatase inhibitor single use cocktail) was added in the cell pellet 
(depending on size of the cell pellet). The cell-lysis buffer suspension was transferred to a 1.5 
ml eppendorf tube and incubated for 30 minutes. The whole protein collection procedure was 
maintained on ice for both conditions, normoxia and hypoxia, to avoid protein degradation. 
Subsequently, the samples were then centrifuged for 15 minutes at 4 oC and maximum speed 
(14,000 rpm) in an eppendorf micro centrifuge. This accumulates the cellular debris into a 
pellet at the bottom of the eppendorf tube. Then, the supernatant, which contains the protein 
was collected and transferred to a new eppendorf tube and stored at -80°C until use. 
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3.3.8 Determination of protein concentration 
The concentration of protein sample concentration was acquired using IR-based Direct 
Detect® assay-free sample cards (Catalogue No. DDAC00010-8P) (version 2.0). All 
measurements were performed using 2μL of sample solution per membrane position. 
Normal lysis buffer was used as a standard and the test sample was loaded in triplicates. 
Unknown protein mixtures were analysed in the “Relative Absorbance” mode, where the 
system delivers information based solely on IR signal strength by Direct Detect® 
spectrometer (Catalogue No. DDHW00010-WW). Empirical sample concentration values 
were determined by interpolation from calibration curves developed for each specific 
protein. 
3.3.9 Sample preparation and SDS-PAGE 
Samples were prepared for SDS-PAGE, where 20-25μg of protein samples was mixed with 
7.5μl of 4x LDS sample buffer and 1μl of reducing agent and distilled water was added until 
the total volume reached 20μl. The mixture was heated for 10 minutes at 75 OC. After sample 
preparation, the extract is ready to be loaded to separate the proteins according to size by gel 
electrophoresis. Precast NuPAGE® (1.5 mm) 4-12% gradient Bis-Tris gels were used to 
separate the polypeptides by size. SDS denatures the protein’s tertiary structure and 
transforms to a linear shape and provides a negative charge that make them migrate towards 
the positive pole in electrophoresis. The white tape at the bottom of the gel cassette was 
removed and then placed in the slot of the Novex® mini-cell gel chamber (Invitrogen). The 
chamber of the tank was blocked by a barrage and locked. The inner chamber was assembled 
first and filled with freshly prepared 50ml 1X NuPAGE® MOPS Running Buffer including 
500μl of antioxidant and the outer chamber was filled with of previously used running buffer 
(approximately 450 ml).  The comb of the wells was removed carefully by pulling upward. 
Subsequently, 10μl of SeeBlue® plus2 pre-stained protein standard ladder followed by 10μl 
of sample mixture was loaded in each well. The lid was fit onto the tank and plugged into 
the power source and the electrophoresis was run for about one and half hour (150V). 
Electrophoresed gel was drawn from the gel cassette and the tank was rinsed with UF 
(Ultrafiltration) water. 
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Table 12: Loading mixture for SDS-PAGE 
Reagent Reduced sample 
Sample x l 
Tris-Glycine SDS Sample Buffer (2X) 5 l 
NuPAGE® Reducing agent (10X) 1 l 
Deionized water to 4 l 
Total volume 10 l 
 
3.3.10 Procedure of electron transfer of proteins 
In electrophoretic transfer, an electric field was employed to elute the proteins from 
electrophoresed gel and transfer them to the nitrocellulose membrane (blotting). A set of 
blotting sponge pads, filter paper, the SDS-Gel, 0.2 μm nitrocellulose membrane were soaked 
in transfer buffer and assembled in the way as shown in (Fig.1). Air bubbles formed between 
the gel and the nitrocellulose membrane were removed by gentle rolling using the roller tool. 
The transfer chamber was transferred to a Xcell Sure Lock mini-cell chamber (Invitrogen). 
The transfer chamber was filled with freshly prepared transfer buffer and the outer chamber 
was filled with pre-used transfer buffer. The lid was fit onto the mini gel chamber. Finally, 
the Xcell Sure Lock mini-cell gel chamber was placed on the ice and electrophoresis was run 




Fig. 11 Schematic diagram of electron transfer procedure of protein. 
3.3.11 Ponceau S staining 
After blotting, the nitrocellulose membrane was washed in MilliQ-H2O followed by 
incubation in 0.1% w/v Ponceau S dye for 5 minutes at room temperature to verify that the 
protein had been transferred to the membrane properly. Ponceau S is a coloured dye that 
binds reversibly to proteins and allows to check the efficiency of transferring. Thereafter, the 
membrane was rinsed with MilliQ-H2O and the membrane was cut according to molecular 
weight of the target protein. 
3.3.12 Blocking, antibody incubation and detection 
The nitrocellulose membrane was washed in desired amount of washing buffer 1x TBS in 
room temperature. Then the membrane was cut according to the desired bands and 
incubated with blocking buffer for 1 hour on a shaker in room temperature to avoid 
 45 
nonspecific binding (5% skim milk or BSA (for phosphoprotein) in 1x TBST). The blots were 
incubated with specific primary and secondary antibodies respectively to visualize the 
desired proteins. The antibodies were also diluted (as mentioned in the Table 9) in blocking 
buffer. Thereafter, the blots were incubated with primary antibody solution with agitation 
overnight at 4 oC. On the following day, blots were rinsed 4 times in 1x TBST before adding 
secondary antibodies, 5 minutes each at room temperature. After that, the blots were 
incubated with the HRP labelled secondary antibody (Table 10) for 1 hour. gentle shaking at 
RT and washed again 4 times for 5 minutes with 1x TBST before chemiluminescent detection.  
3.3.13 Chemiluminescence and quantification of protein expression 
Blots were developed with the SuperSignal® West Femto as well as SuperSignal® West Pico 
(Maximum Sensitivity Substrate Chemiluminescent Substrates). The kit contains an 
enhanced chemiluminescent substrate for antibody conjugated horseradish peroxidase 
(HRP) enzyme used for immunoblotting. The blots were allowed to absorb the substrate for 
five minutes before drained the excess wash buffer from the membranes. The development 
was done with a luminescent image analyser, Image Reader LAS-3000 (Fujifilm Medical 
Systems Inc., Stamford, Connecticut, USA). Subsequently, the relative expression levels of 
the proteins were quantified using ImageJ software. Finally, the relative density was 
calculated and analysed for all the samples. The housekeeping gene GAPDH 
(Glyceraldehyde-3 phosphate-dehydrogenase) was used as a loading control to confirm 
equal amount of protein was loaded.  
3.3.14 Immunocytochemistry 
Immunocytochemistry (ICC) is a technique for detecting a protein of interest inside or on the 
membrane of cells. The protein is identified by using an antibody conjugated to a fluorescent 
tag – a fluorophore. Immunostaining can then be investigated using different techniques, for 
example fluorescence microscopy and confocal microscopy. One can distinguish between 
direct and indirect ICC. In direct ICC, only a primary fluorophore-conjugated antibody is 
used. In indirect ICC, a primary antibody is allowed to bind to the target protein first, and 
then a secondary fluorophore-conjugated antibody binds to the primary antibody. Indirect 
 46
ICC is more sensitive because several secondary antibodies can bind to a single primary 
antibody, thus enhancing the signal. 
3.3.15 Preparation of cells for immunostaining and Matrigel coating 
Cell culture was done in 1% O2 and 21% CO2 (Hypoxia) and in the standard tissue culture 
incubator. Cells were kept on ice after removal from the hypoxia chamber. Following the 
normal procedure of cell culture the cells were splitted for fixation. Prepared desired amount 
of Matrigel matrix (Corning Matrigel matrix is a reconstituted basement membrane 
preparation that is extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a 
tumor rich in extracellular matrix proteins) which was diluted in NB medium (Neurobasal 
medium) without growth factors.  Subsequently, Matrigel coating was done by pipetting 2 
ml droplets of the mixture (NB medium + matrigel) solution onto 18 x 18 mm glass cover slips 
in 6-well plates (which was planned for normoxia, hypoxia and hypoxia with inhibitor in 
different concentrations) and incubated for 30 minutes at 37 oC. 
3.3.16 Procedure of Immunostaining 
Cells cultured on poly-L-lysine (Sigma-Aldrich)-coated coverslips were fixed for 10 min 
using 4% formaldehyde or 100% methanol. After 3 times washing with cold PBS, cells were 
permeabilized with 0.1% Triton (Sigma-Aldrich) in PBS, washed again with PBS followed by 
a blocking step for 1 hour with PBS + 0.1% Tween-20 (Sigma-Aldrich), 2% bovine serum 
albumin (BSA) and 1: 50 dilution of normal goat serum (Dako Denmark A/S, Glostrup, 
Denmark). Subsequently, cells were incubated with the indicated primary antibody HIF1A 
(diluted 1:500 in dilution buffer) at room temperature for 1.5 hours. After 3 times washing 
with PBS, slides were incubated for 1 h with the appropriate secondary antibody, goat anti-
rabbit Alexa 488 (light sensitive) (diluted 1:200 in dilution buffer). After washing 3x5 times 
with PBST and 2x5 times with PBS, the cover slips were mounted on microscope slides 
25x75x1 mm with 5μM of Prolong Gold antifade reagent containing DAPI (DAPI stains the 
nucleus of the cell by binding to DNA). The mounting solution was allowed to dry for 
overnight at RT in dark. Cells were examined by fluorescent microscopy (Leica DM6000, 
Leica Microsystems GmbH, Mannheim, Germany) and images were captured using Leica 
DFC360 FX camera. 
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3.3.17 Immunohistochemistry 
Formalin fixed paraffin-embedded 3 μm thick consecutive tissue sections were mounted on 
microscope slides and dried overnight at 55 °C. Tissue sections were deparaffinized in xylol 
and rehydrated in graded series of ethanol, and stained with hematoxylin and eosin (HE). 
Tissue labelling was performed using the DiscoveryXT immunohistochemistry system 
(Ventana/Roche, Strasbourg, France). Antigen retrieval was performed using microwave pre- 
treatment in pH 6.0 citrate buffer. Sections were treated with 0.3% H2O2 for 30 min and 
blocked for 1 h with 2% BSA to reduce non-specific primary antibody binding. Next, 
incubated with the primary antibody anti-caveoline-1 (rabbit) overnight at 4 °C. 
As negative controls, primary antibodies were omitted. After incubation with primary 
antibody, secondary rabbit anti-goat IgG (H+L) antibody were used. Staining was visualized 
by 3,3′-diaminobenzidine and sections were counterstained with hematoxylin and mounted. 
Images of relevant sections were acquired using a C9600 NanoZoomer (Hamamatsu 
Photonics KK, Hamamatsu City, Japan). 
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4. Result  
4.1 Cav-1 expression and correlation with mesenchymal and proneural 
markers in GBM TCGA data. 
The analysis of GBM TCGA data using the online tool “betastasis.com” showed a correlation 
of Cav-1 expression with mesenchymal markers CEBPB, CD44, CHI3L1 (YKL40) and STAT3 
(Fig. 12). In contrast, analysis of proneural markers olig2, DLL3, ASCL1 and PDGFRA 
showed anti-correlation with Cav-1 expression (Fig. 13). This indicated that Cav-1 might be 
upregulated in GBM of the mesenchymal subtype. 
 
Fig. 12 GBM TCGA analysis of mesenchymal markers and correlation with Cav1 expression. Pearson correlation 
co-efficient is indicated. 
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Fig. 13 GBM TCGA analysis of proneural markers and correlation with Cav-1 expression. Pearson correlation co-
efficient is indicated. 
4.2 Assessment of Cav-1 expression under normoxia and hypoxia 
Cav-1 expression was evaluated in a panel of GBM cell lines including GG14, BG7, BG5, GG16 
and S24 under normoxic and hypoxic conditions. We observed that Cav-1 is strongly 
upregulated in GG14 and BG7 cell lines in hypoxia compared to normoxia. In contrast, S24 
showed higher levels of Cav-1 in normoxia compared to hypoxia. There was no difference in 
cav-1 expression in GG16 and BG5 cells.  
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Fig. 14 Cav-1 expression under normoxic and hypoxic conditions in different human GBM cell lines. Western blot 
for Cav-1. GAPDH was used as a control. 
4.3 Heterogeneity of Cav1 expression in GBM patient samples 
To confirm our results from the cell lines, we performed immunohistochemistry staining in 
different human GBM tissue samples. Cav-1 is clearly upregulated around necrotic areas 
(hypoxic) areas in GBMs of patient 1, 2, and 5, while in patient 3, 4, and 6, Cav-1 expression 






Fig. 15 Expression pattern of Cav-1 in human GBM patient samples. Xenograft tumor tissues derived from GBM 
human cell lines from different human patient samples. Representative Cav-1 IHC staining from a tissue showing 
Caveolin-1 is clearly upregulated in GBM patient sample 1, 2 and 5, while Cav-1 expression is restricted to blood 
vessels in patient 3, 4 and 6 respectively. 
4.4 Induction of HIF-1α under hypoxia 
To verify that GBM cell lines upregulate HIF-1α under hypoxia (1% O2 for 72 hours), we 
performed western blot for HIF-1α under nomoxic and hypoxic conditions for BG5, GG16 
and S24 cell lines (Fig. 16). In all 3 cell lines HIF-1α was upregulated under hypoxia compared 
to normoxia. 
 
Fig. 16 Hypoxia induces upregulation of HIF-1α in GBM cell lines. Western blot for HIF-1α. GAPDH was used 
as a control. 
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4.5 Nuclear translocation of HIF-1α under hypoxia can be blocked by 
Digoxin 
To investigate, if the HIF-1α inhibitor digoxin, a cardiac glycoside, could block the nuclear 
localization of HIF-1α, BG7 cells were examined under normoxia and hypoxia with or 
without digoxin by immunofluorescence. Digoxin is known to have modest effects on global 
protein synthesis but very potently inhibit HIF-1α mRNA translation.99 A concentration of 
150 nM Digoxin, which has been published previously to be effective (concentration, was 
added 1 hr prior to placing the BG7 cells under hypoxia for 18 hrs. Our Immunofluorescence 
data showed that the hypoxia-enhanced nuclear translocation of HIF-1α was slightly 
inhibited by digoxin (150 nM) compared to hypoxia without digoxin. 
 
Fig. 17 All the representative images were acquired after 18 hours of incubation of the cells with drugs 
and control at 63x magnification. Staining was visualized by DAPI for hypoxic condition. Here we found, 
under hypoxic condition with 18hrs time period, digoxin (150nM concentration) could block the nuclear 
traslocation of HIF-1α but not completely and under normoxic conditions little or no nuclear expression 
of these transcription factors was detected. 
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4.6 Hypoxia induces a downregulation of proneural markers in GBM 
cells 
 
Fig. 18 Western blot analysis of different mesenchymal and proneural markers under normoxic and hypoxic 
conditions.  
To explore whether hypoxia induced a proneural to mesenchymal transition in parallel to the 
upregulation of Cav-1, we performed western blot analyses from lysates of 5 different GBM 
cell lines for YKL40, pSTAT3, CD44 as representative mesenchymal markers along with 
proneural markers such as PDGFRA, Olig2 and EZH2 under normoxic and hypoxic 
conditions (1% O2) for 72 hours. The proneural markers olig2 and PDGFRA were 
downregulated under hypoxic compared to normoxic conditions in all cell lines. The 
mesenchymal markers YKL40, CD44, pSTAT3 and EZH2 did not show such uniform pattern 
across the cell lines. Although YKL40 was upregulated in BG5 and S24 under hypoxia, Cav-
1 was not upregulated in these cell lines under hypoxia. In S24, Cav-1 was even 
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downregulated under hypoxia. pSTAT3 was downregulated in BG5, GG16 and S24 under 
hypoxia while it did not show any change in BG7 and GG16. EZH2 and CD44 did not show 










The Cancer Genome Atlas Research Network (TCGA) first studied systematically 
Glioblastoma (GBM). The early publication from them in 2008 presented the results of 
genomic and transcriptomic analysis of 206 GBMs, including mutation sequencing of 600 
genes in 91 samples.100 
To study glioblastoma, several research groups are working on high dimensional gene 
profiling studies. For instance, studies examining copy number alterations101 and gene 
expression profiling studies which identify gene signatures associated with EGFR 
overexpression, clinical features, and survival102-104  
The advancements in genomic sequencing and transcriptome analysis have classified GBM 
into different molecular subtypes such as i) proneural, ii) classical iii) mesenchymal and iv) 
neural subtypes. These subtype names were chosen based on prior naming and the 
expression of signature genes.105 The studies have established that overexpression of a 
mesenchymal gene expression signature (MGES) and loss of a proneural gene expression 
signature (PNGES) co-segregate with the poor prognosis group of glioma patients.106 
A mesenchymal phenotype in GBM has been associated with tumour aggressiveness and 
elevated invasive potential. Interestingly, high levels of tumour necrosis were observed in 
tumours of patients having a mesenchymal subtype.107 
A recent study proposed categorization of HIF regulated genes into those involving 
transcription factors, chromatin modifiers, enzymes, receptors, small GTPases, transporters 
adhesion molecules, surface molecules, membrane proteins, and miRs. Moreover, these genes 
have been shown to play a key role in the process of EMT and tumor metastasis. Hypoxic 
regions are frequently found in GBM and the presence of extensive hypoxic areas has been 
associated with worse prognosis in GBM patients, which has been linked to hypoxic cancer 
cells displaying a more malignant phenotype and being more resistant to chemotherapy and 
radiation.108 The HIF transcription factors are instrumental for orchestrating adaptive 
responses to cope with oxygen shortage, and particularly HIF-1α is key in inducing 
expression of glycolytic enzymes and several angiogenic growth factors.109 HIF-1α was found 
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to be upregulated in many of the malignant tumours primarily by hypoxia-mediated protein 
stabilization.110 
In our study, we verified that HIF-1α was upregulated in primary GBM cell lines under 
hypoxia. Secondly, we observed that the hypoxia-induced expression of HIF-1α was 
suppressed by digoxin. Our immunoflurescence results demonstrated that under hypoxic 
conditions HIF-1α nuclear translocation was markedly inhibited by digoxin (150 nM) 
compared to hypoxia without digoxin. These data indicate that digoxin is a potent HIF-1α 
inhibitor which can reduce nuclear translocation of HIF-1α in BG7 cells. Immunofluorescence 
analysis highlighted HIF-1α immuno-reactivity predominantly in the nucleus based on DAPI 
counterstaining. However, the mechanisms of HIF-1α regulation remain unclear. Thus, 
future work needed to better understand the signalling pathways in HIF-1α regulation 
caused by cardiac glycosides (digoxin) under hypoxic conditions. Our results are consistent 
with some extent to the reported one. 111 
In GBM, HIF-1α seems to be primarily localized to the pseudopalisading cells around necrotic 
cores and to tumour cells at the invasive edge of the tumour that infiltrate the normal brain 
tissue [36]. Extensive necrosis and elevated levels of HIF-regulated genes are features that 
were more frequently found in mesenchymal GBM when compared to proneural GBM.106 
Despite the association between hypoxia and mesenchymal GBM, the potential molecular 
mediators that induce a mesenchymal shift are not fully characterized. In our study, we 
showed that proneural markers were downregulated under hypoxia across the cell lines 
while the regulation pattern for mesenchymal markers was more complex. Interestingly, 
overall, there was no clear upregulation of mesenchymal markers under hypoxia.  
In our report, we found Cav-1 might be upregulated in GBM of the mesenchymal subtypes 
by the analysis of GBM TCGA data using the online tool “betastasis.com”. The data showed 
a correlation of Cav-1 expression with mesenchymal markers CEBPB, CD44, CHI3L1 (YKL40) 
and STAT3 and in contrast, analysis of proneural markers olig2, DLL3, ASCL1 and PDGFRA 
showed anti-correlation with Cav-1 expression. 
Recent studies revealed that Caveolin-1 (Cav-1) is a critical regulator of tumor progression in 
a variety of cancers including glioblastoma multiforme where it has been implicated as either 
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a tumor suppressor or tumor promoter. Quann et al. showed significant upregulation of Cav-
1 where genes are responsible for negative regulation of signal transduction, particularly 
within ERK, PI3K/AKT and mTOR pathways.112 They also suggested that it has the capability 
to separate PI3K and mTOR activity. They also showed that ERK, PI3K and mTOR signaling 
axes are frequently upregulated in GBM. This suggests that loss of Cav-1 could lead to 
unchecked activation of these pathways.  
In another report,113 Cav-1 was able to affect the TGF pathway in glioblastoma cells. In 
U87MG cells, depletion of Cav-1 was associated with an increased secretion of TGF1, an 
increased expression of TGF-RI and an increased phosphorylation of Smad2. Opposite 
effects were observed when caveolin-1 was overexpressed. They suggested that Cav-1 
controls the secretion of TGF, the expression of TGFRI and the activation status of Smad2 
in U87MG cells.  
Bailey and Liu also found that Cav-1 is up-regulated following induction of EMT.114 Their 
results revealed that cells elongate and start to scatter prior to the up-regulation of Cav-1, 
suggesting that changes in Cav-1 expression may be a product of EMT. 
Recently, Talasila et al. showed that Cav-1 is one of the top genes upregulated in the 
mesenchymal subtypes by gene expression data. Similarly, in our study, we observed that 
Cav-1 is strongly upregulated in GG14 and BG7 cell lines in hypoxia compared to normoxia. 
In contrast, S24 showed higher levels of Cav-1 in normoxia compared to hypoxia. There was 
no difference in Cav-1 expression in GBM cell lines including GG16 and BG5. This shows that 
Cav-1 expression and regulation can be very heterogenous between different GBM samples. 
We observed the same heterogeneity in tissue from patient samples, where Cav-1 was 
upregulated in hypoxic areas, however, not in all patient samples analysed. Future studies 
need to be performed to show if there is any correlation to specific mutations regarding the 
difference in Cav-1 expression.  
Tissue hypoxia is caused by insufficient oxygen delivery, leading to activation of hypoxia-
inducible factor (HIF). A wide range of HIF target genes was critical in the control of 
metabolism, cell proliferation, cell survival, angiogenesis, and iron uptake.115 Hypoxia and 
necrosis both play key roles in tumor progression and resistance to treatment.  However, in 
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vivo tumor growth is also characterized by the presence of ischemic and necrotic areas 
generated by oxygenation gradients and differential access to nutrients.116 In our report, we 
performed IHC staining with several GBM tissue samples which were taken from 6 different 
patients to investigate the upregulation of Cav-1. We found from our investigation that Cav-
1 is clearly upregulated in 3 GBM patient samples. In contrast, Cav-1 expression is restricted 
to blood vessels in other 3 patient samples. 
Chiu et al. showed the relationship between pSTAT3 and Cav-1 and their clinical significance 
in human breast cancer brain metastasis.117 They analysed several human breast cancer brain 
metastases samples which strongly suggested that activated STAT3 can binds directly to the 
Cav-1 promoter and inhibit its transcription. On the other hand, it was also showed that Cav-
1 negatively regulates activation of STAT3 and invasion of brain-metastatic cancer cells. 
However, suppression of STAT3 activation inhibited the invasion and brain metastases of 
breast cancer cells in animal model. In our investigation, we found that pSTAT3 was 
downregulated in GBM cell lines including BG5, GG16 and S24 under hypoxia while it did 
not show any change in BG7 and GG16 cells.  
The overlap of multiple hypoxia and mesenchymal signalling molecules and their integral 
role in the regulation of CSCs and the tumour microenvironment in GBM suggest the 
importance of understanding these mechanisms in designing future targeted therapies. 
Current evidence supports a mesenchymal subtype of GBM, which can evolve from other 
subtypes and portends a poorer clinical prognosis. Moreover, hypoxia and mesenchymal 
transformation involve multiple potentially targetable pathways and molecules.59 The 
mesenchymal subclass has been associated with increased hypoxia and worse outcome. We 
have previously shown that HIF-1α is a central regulator of the genes upregulated in the 
angiogenic/mesenchymal tumors of our mode. 
 59 
6. References 
1. Chial, H. Genetic regulation of cancer. Nature Education 1 (2008). 
2. http://www.who.int/en/news-room/fact-sheets/detail/cancer 
3. Ahmedin, J. et al. Global cancer statistics. CA: A Cancer Journal for 
Clinicians 61, 69-90 (2011). 
4. Jacques, F. et al. Cancer incidence and mortality worldwide: Sources, methods 
and major patterns in GLOBOCAN 2012. International Journal of Cancer 
136, E359-E386 (2015). 
5. Lengauer, C., Kinzler, K.W. & Vogelstein, B. Genetic instabilities in human 
cancers. Nature 396, 643 (1998). 
6. Hanahan, D. & Weinberg, Robert A. Hallmarks of Cancer: The Next 
Generation. Cell 144, 646-674 (2011). 
7. Pavlova, Natalya N. & Thompson, Craig B. The Emerging Hallmarks of 
Cancer Metabolism. Cell Metabolism 23, 27-47 (2016). 
8. Pecorino, L. Molecular biology of cancer : mechanisms, targets, and 
therapeutics, Edn. Fourth edition. (Oxford University Press, Oxford, United 
Kingdom; 2016). 
9. Muller, P.A.J., Vousden, K.H. & Norman, J.C. p53 and its mutants in tumor 
cell migration and invasion. The Journal of Cell Biology 192, 209 (2011). 
10. Steeg, P.S. Tumor metastasis: mechanistic insights and clinical challenges. 
Nature Medicine 12, 895 (2006). 
11. Ribatti, D., Mangialardi, G. & Vacca, A. Stephen Paget and the ‘seed and soil’ 
theory of metastatic dissemination. Clinical and Experimental Medicine 6, 
145-149 (2006). 
12. Ohgaki, H. & Kleihues, P. Population-based studies on incidence, survival 
rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J 
Neuropathol Exp Neurol 64, 479-489 (2005). 
13. Louis, D.N. et al. The 2007 WHO Classification of Tumours of the Central 
Nervous System. Acta Neuropathologica 114, 97-109 (2007). 
14. Ostrom, Q.T. et al. CBTRUS Statistical Report: Primary Brain and Central 
Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro 
Oncol 17 Suppl 4, iv1-iv62 (2015). 
15. Stupp, R. et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide 
for Glioblastoma. New England Journal of Medicine 352, 987-996 (2005). 
16. Friedmann-Morvinski, D. et al. Targeting NF-κB in glioblastoma: A 
therapeutic approach. Science Advances 2 (2016). 
17. Kupp, R. et al. Lineage-Restricted OLIG2-RTK Signaling Governs the 
Molecular Subtype of Glioma Stem-like Cells. Cell Reports 16, 2838-2845 
(2016). 
18. Wen, P.Y. & Kesari, S. Malignant Gliomas in Adults. New England Journal of 
Medicine 359, 492-507 (2008). 
19. Earle, K.M. The proper nomenclature for glioblastoma multiforme. Int J 
Radiat Oncol Biol Phys 1, 805-808 (1976). 
 60
20. Panjabi, M.M., Dicker, D.B. & Dohrmann, G.J. Biomechanical quantification 
of experimental spinal cord trauma. Journal of Biomechanics 10, 681-687 
(1977). 
21. Iacob, G. & Dinca, E.B. Current data and strategy in glioblastoma multiforme. 
J Med Life 2, 386-393 (2009). 
22. Zhen, L., Yufeng, C., Zhenyu, S. & Lei, X. Multiple extracranial metastases 
from secondary glioblastoma multiforme: a case report and review of the 
literature. Journal of Neuro-Oncology 97, 451-457 (2010). 
23. Moorthy, R.K. & Rajshekhar, V. Development of glioblastoma multiforme 
following traumatic cerebral contusion: case report and review of literature. 
Surgical Neurology 61, 180-184 (2004). 
24. Cobbs, C.S. Evolving evidence implicates cytomegalovirus as a promoter of 
malignant glioma pathogenesis. Herpesviridae 2, 10 (2011). 
25. Cobbs, C.S. et al. Human Cytomegalovirus Infection and Expression in 
Human Malignant Glioma. Cancer Research 62, 3347 (2002). 
26. Spinelli, V. et al. Occupational and environmental risk factors for brain 
cancer: a pilot case-control study in France. La Presse Médicale 39, e35-e44 
(2010). 
27. Urbańska, K., Sokołowska, J., Szmidt, M. & Sysa, P. Glioblastoma multiforme 
– an overview. Contemporary Oncology/Współczesna Onkologia 18, 307-312 
(2014). 
28. Wrensch, M., Minn, Y., Chew, T., Bondy, M. & Berger, M.S. Epidemiology 
of primary brain tumors: current concepts and review of the literature. Neuro 
Oncol 4, 278-299 (2002). 
29. Evans, S.M. et al. Hypoxia Is Important in the Biology and Aggression of 
Human Glial Brain Tumors. Clinical Cancer Research 10, 8177 (2004). 
30. Cooper, L.A.D. et al. The Tumor Microenvironment Strongly Impacts Master 
Transcriptional Regulators and Gene Expression Class of Glioblastoma. The 
American Journal of Pathology 180, 2108-2119 (2012). 
31. Brat, D.J. et al. Pseudopalisades in Glioblastoma Are Hypoxic, Express 
Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell 
Population. Cancer Research 64, 920 (2004). 
32. Teicher, B.A. Hypoxia and drug resistance. Cancer and Metastasis Reviews 
13, 139-168 (1994). 
33. Ohgaki, H. Epidemiology of Brain Tumors, in Cancer Epidemiology: 
Modifiable Factors. (ed. M. Verma) 323-342 (Humana Press, Totowa, NJ; 
2009). 
34. Kabat, G.C., Etgen, A.M. & Rohan, T.E. Do Steroid Hormones Play a Role in 
the Etiology of Glioma Cancer Epidemiology Biomarkers &amp;amp; 
Prevention 19, 2421 (2010). 
35. Tso, C.-L. et al. Distinct Transcription Profiles of Primary and Secondary 
Glioblastoma Subgroups. Cancer Research 66, 159 (2006). 
36. Ladha, J. et al. Glioblastoma-Specific Protein Interaction Network Identifies 
PP1A and CSK21 as Connecting Molecules between Cell Cycle–Associated 
Genes. Cancer Research 70, 6437 (2010). 
 61 
37. Phillips, H.S. et al. Molecular subclasses of high-grade glioma predict 
prognosis, delineate a pattern of disease progression, and resemble stages in 
neurogenesis. Cancer Cell 9, 157-173 (2006). 
38. Louis, D.N. et al. The 2016 World Health Organization Classification of 
Tumors of the Central Nervous System: a summary. Acta Neuropathologica 
131, 803-820 (2016). 
39. Hiroko, O. & Paul, K. Genetic alterations and signaling pathways in the 
evolution of gliomas. Cancer Science 100, 2235-2241 (2009). 
40. Oberndorfer, S. et al. The End-of-Life Hospital Setting in Patients with 
Glioblastoma. Journal of Palliative Medicine 11, 26-30 (2008). 
41. Sizoo, E.M. et al. Symptoms and problems in the end-of-life phase of high-
grade glioma patients. Neuro Oncol 12, 1162-1166 (2010). 
42. Lakhan, S.E. & Harle, L. Difficult diagnosis of brainstem glioblastoma 
multiforme in a woman: a case report and review of the literature. Journal of 
Medical Case Reports 3, 87 (2009). 
43. Larjavaara, S. et al. Incidence of gliomas by anatomic location. Neuro Oncol 
9, 319-325 (2007). 
44. Drevelegas, A. Imaging of Brain Tumors with Histological Correlations, Edn. 
2 nd. (Springer-Verlag, Berlin Heidelberg; 2011). 
45. Kleihues, P., Cavenee, W.K. & International Agency for Research on Cancer. 
Pathology and genetics of tumours of the nervous system. (IARC Press, Lyon; 
2000). 
46. Puli, S., Lai, J.C.K. & Bhushan, A. Inhibition of matrix degrading enzymes 
and invasion in human glioblastoma (U87MG) Cells by isoflavones. Journal 
of Neuro-Oncology 79, 135-142 (2006). 
47. Kesari, S. Understanding Glioblastoma Tumor Biology: The Potential to 
Improve Current Diagnosis and Treatments. Seminars in Oncology 38, S2-S10 
(2011). 
48. Mammoto, T. et al. Role of Collagen Matrix in Tumor Angiogenesis and 
Glioblastoma Multiforme Progression. The American Journal of Pathology 
183, 1293-1305 (2013). 
49. Codrici, E., Enciu, A.-M., Popescu, I.-D., Mihai, S. & Tanase, C. Glioma Stem 
Cells and Their Microenvironments: Providers of Challenging Therapeutic 
Targets. Stem Cells International 2016, 20 (2016). 
50. Hu, M. & Polyak, K. Microenvironmental regulation of cancer development. 
Current Opinion in Genetics & Development 18, 27-34 (2008). 
51. Chen, J.L.-Y. et al. The Genomic Analysis of Lactic Acidosis and Acidosis 
Response in Human Cancers. PLOS Genetics 4, e1000293 (2008). 
52. Bar, E.E., Lin, A., Mahairaki, V., Matsui, W. & Eberhart, C.G. Hypoxia 
Increases the Expression of Stem-Cell Markers and Promotes Clonogenicity in 
Glioblastoma Neurospheres. The American Journal of Pathology 177, 1491-
1502 (2010). 
53. Thambi, T., Park, J.H. & Lee, D.S. Hypoxia-responsive nanocarriers for 
cancer imaging and therapy: recent approaches and future perspectives. 
Chemical Communications 52, 8492-8500 (2016). 
 62
54. Wan, J.U.N., Wu, W.E.I. & Zhang, R. Local recurrence of small cell lung 
cancer following radiofrequency ablation is induced by HIF-1α expression in 
the transition zone. Oncology Reports 35, 1297-1308 (2016). 
55. Tonissi, F. et al. Reoxygenation Reverses Hypoxia-related Radioresistance in 
Head and Neck Cancer Cell Lines. Anticancer Res 36, 2211-2215 (2016). 
56. Semenza, G.L. Oxygen Sensing, Hypoxia-Inducible Factors, and Disease 
Pathophysiology. Annual Review of Pathology: Mechanisms of Disease 9, 47-
71 (2014). 
57. Wenger, R.H., Stiehl, D.P. & Camenisch, G. Integration of Oxygen Signaling 
at the Consensus HRE. Science&#039;s STKE 2005, re12 (2005). 
58. Colwell, N. et al. Hypoxia in the glioblastoma microenvironment: shaping the 
phenotype of cancer stem-like cells. Neuro Oncol 19, 887-896 (2017). 
59. Karsy, M., Guan, J., Jensen, R., Huang, L.E. & Colman, H. The Impact of 
Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and 
Cancer Stem Cells Regulation. World Neurosurgery 88, 222-236 (2016). 
60. Rong, Y., Durden, D.L., Van Meir, E.G. & Brat, D.J. 'Pseudopalisading' 
necrosis in glioblastoma: a familiar morphologic feature that links vascular 
pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65, 529-539 
(2006). 
61. Kahlert, U.D. et al. Activation of canonical WNT/&#x3b2;-catenin signaling 
enhances <em>in vitro</em> motility of glioblastoma cells by activation of 
ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer 
Letters 325, 42-53 (2012). 
62. Kahlert, U.D., Nikkhah, G. & Maciaczyk, J. Epithelial-to-mesenchymal(-like) 
transition as a relevant molecular event in malignant gliomas. Cancer Lett 331, 
131-138 (2013). 
63. Iwadate, Y. Epithelial-mesenchymal transition in glioblastoma progression. 
Oncology Letters 11, 1615-1620 (2016). 
64. Parat, M.-O. & Riggins, G.J. Caveolin-1, caveolae, and glioblastoma. Neuro-
Oncology 14, 679-688 (2012). 
65. Tiwari, A. et al. Caveolin-1 is an aggresome-inducing protein. Sci Rep 6, 
38681 (2016). 
66. Williams, T.M. & Lisanti, M.P. The Caveolin genes: from cell biology to 
medicine. Annals of Medicine 36, 584-595 (2004). 
67. Hill, M.M. et al. PTRF-Cavin, a Conserved Cytoplasmic Protein Required for 
Caveola Formation and Function. Cell 132, 113-124 (2008). 
68. Bastiani, M. et al. MURC/Cavin-4 and cavin family members form tissue-
specific caveolar complexes. The Journal of Cell Biology 185, 1259 (2009). 
69. Salem, A.F. et al. Caveolin-1 promotes pancreatic cancer cell differentiation 
and restores membranous E-cadherin via suppression of the epithelial-
mesenchymal transition. Cell Cycle 10, 3692-3700 (2011). 
70. Deurs, B.v., Roepstorff, K., Hommelgaard, A.M. & Sandvig, K. Caveolae: 
anchored, multifunctional platforms in the lipid ocean. Trends in Cell Biology 
13, 92-100 (2003). 
71. Martin, S. et al. Caveolin-1 regulates glioblastoma aggressiveness through the 
control of α5β1 integrin expression and modulates glioblastoma 
 63 
responsiveness to SJ749, an α5β1 integrin antagonist. Biochimica et 
Biophysica Acta (BBA) - Molecular Cell Research 1793, 354-367 (2009). 
72. Scherer, P.E., Williams, S., Fogliano, M., Baldini, G. & Lodish, H.F. A novel 
serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 
270, 26746-26749 (1995). 
73. Michel, V. & Bakovic, M. Lipid rafts in health and disease. Biology of the Cell 
99, 129-140 (2012). 
74. Shatz, M. & Liscovitch, M. Caveolin-1: a tumor-promoting role in human 
cancer. Int J Radiat Biol 84, 177-189 (2008). 
75. Patel, H.H., Murray, F. & Insel, P.A. Caveolae as Organizers of 
Pharmacologically Relevant Signal Transduction Molecules. Annual Review of 
Pharmacology and Toxicology 48, 359-391 (2008). 
76. Gupta, R., Toufaily, C. & Annabi, B. Caveolin and cavin family members: 
Dual roles in cancer. Biochimie 107, 188-202 (2014). 
77. Chatterjee, M. et al. Caveolin-1 is Associated with Tumor Progression and 
Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. 
Scientific Reports 5, 10867 (2015). 
78. Koleske, A.J., Baltimore, D. & Lisanti, M.P. Reduction of caveolin and 
caveolae in oncogenically transformed cells. Proceedings of the National 
Academy of Sciences 92, 1381 (1995). 
79. Galbiati, F. et al. Targeted downregulation of caveolin‐1 is sufficient to drive 
cell transformation and hyperactivate the p42/44 MAP kinase cascade. The 
EMBO Journal 17, 6633 (1998). 
80. Sunaga, N. et al. Different Roles for Caveolin-1 in the Development of Non-
Small Cell Lung Cancer 
&lt;strong&gt;&lt;em&gt;versus&lt;/em&gt;&lt;/strong&gt; Small Cell Lung 
Cancer. Cancer Research 64, 4277 (2004). 
81. Navarro, A., Anand-Apte, B. & Parat, M.-O. A role for caveolae in cell 
migration. The FASEB Journal 18, 1801-1811 (2004). 
82. Laflamme, M.A. et al. Formation of Human Myocardium in the Rat Heart 
from Human Embryonic Stem Cells. The American Journal of Pathology 167, 
663-671 (2005). 
83. Schwarz, B.T. et al. LIGHT Signals Directly to Intestinal Epithelia to Cause 
Barrier Dysfunction via Cytoskeletal and Endocytic Mechanisms. 
Gastroenterology 132, 2383-2394 (2007). 
84. Song, L., Ge, S. & Pachter, J.S. Caveolin-1 regulates expression of junction-
associated proteins in brain microvascular endothelial cells. Blood 109, 1515 
(2007). 
85. Griffoni, C. et al. Knockdown of Caveolin-1 by Antisense Oligonucleotides 
Impairs Angiogenesis in Vitro and in Vivo. Biochemical and Biophysical 
Research Communications 276, 756-761 (2000). 
86. Beardsley, A. et al. Loss of caveolin-1 polarity impedes endothelial cell 
polarization and directional movement. J Biol Chem 280, 3541-3547 (2005). 
87. Holdhoff, M. et al. Use of personalized molecular biomarkers in the clinical 
care of adults with glioblastomas. Journal of Neuro-Oncology 110, 279-285 
(2012). 
 64
88. Rodriguez, O.C. et al. Dietary downregulation of mutant p53 levels via 
glucose restriction. Cell Cycle 11, 4436-4446 (2012). 
89. Sotgia, F. et al. Understanding the Warburg effect and the prognostic value of 
stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast 
Cancer Research 13, 213 (2011). 
90. Tanowitz, H.B., Machado, F.S. & Albanese, C. An expanded role for 
Caveolin-1 in brain tumors. Cell Cycle 12, 1485-1486 (2013). 
91. Ohgaki, H. & Kleihues, P. Genetic Pathways to Primary and Secondary 
Glioblastoma. The American Journal of Pathology 170, 1445-1453 (2007). 
92. Volonte, D. et al. Caveolin-1 promotes the tumor suppressor properties of 
oncogene-induced cellular senescence. J Biol Chem 293, 1794-1809 (2018). 
93. Jenkins, R.B. et al. A Molecular Cytogenetic Analysis of 7q31 in Prostate 
Cancer. Cancer Research 58, 759 (1998). 
94. Zenklusen, J.C., Thompson, J.C., Klein-Szanto, A.J.P. & Conti, C.J. Frequent 
Loss of Heterozygosity in Human Primary Squamous Cell and Colon 
Carcinomas at 7q31.1: Evidence for a Broad Range Tumor Suppressor Gene. 
Cancer Research 55, 1347 (1995). 
95. Zenklusen, J.C., Thompson, J.C., Troncoso, P., Kagan, J. & Conti, C.J. Loss of 
Heterozygosity in Human Primary Prostate Carcinomas: A Possible Tumor 
Suppressor Gene at 7q31.1. Cancer Research 54, 6370 (1994). 
96. Cohen, A.W., Hnasko, R., Schubert, W. & Lisanti, M.P. Role of Caveolae and 
Caveolins in Health and Disease. Physiological Reviews 84, 1341-1379 
(2004). 
97. Tanowitz, H.B., Machado, F.S., Avantaggiati, M.L. & Albanese, C. An 
expanded role for Caveolin-1 in brain tumors. Cell Cycle 12, 1485-1486 
(2013). 
98. Talasila, K.M. et al. The angiogenic switch leads to a metabolic shift in human 
glioblastoma. Neuro-Oncology 19, 383-393 (2017). 
99. Zhang, H. et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis 
and block tumor growth. Proceedings of the National Academy of Sciences 
105, 19579 (2008). 
100. Brennan, Cameron W. et al. The Somatic Genomic Landscape of 
Glioblastoma. Cell 155, 462-477 (2013). 
101. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in 
cancer: Methodology and application to glioma. Proceedings of the National 
Academy of Sciences 104, 20007 (2007). 
102. Freije, W.A. et al. Gene Expression Profiling of Gliomas Strongly Predicts 
Survival. Cancer Research 64, 6503 (2004). 
103. Liang, Y. et al. Gene expression profiling reveals molecularly and clinically 
distinct subtypes of glioblastoma multiforme. Proceedings of the National 
Academy of Sciences of the United States of America 102, 5814 (2005). 
104. Mischel, P.S. et al. Identification of molecular subtypes of glioblastoma by 
gene expression profiling. Oncogene 22, 2361 (2003). 
105. Hodgson, J.G. et al. Comparative analyses of gene copy number and mRNA 
expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol 
11, 477-487 (2009). 
 65 
106. Carro, M.S. et al. The transcriptional network for mesenchymal transformation 
of brain tumours. Nature 463, 318 (2009). 
107. Verhaak, R.G.W. et al. Integrated Genomic Analysis Identifies Clinically 
Relevant Subtypes of Glioblastoma Characterized by Abnormalities in 
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010). 
108. Hsieh, C.H. et al. NADPH oxidase subunit 4-mediated reactive oxygen species 
contribute to cycling hypoxia-promoted tumor progression in glioblastoma 
multiforme. PLoS One 6, e23945 (2011). 
109. Carmeliet, P. & Jain, R.K. Principles and mechanisms of vessel normalization 
for cancer and other angiogenic diseases. Nat Rev Drug Discov 10, 417-427 
(2011). 
110. Semenza, G.L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer 
Cell 5, 405-406 (2004). 
111. Wei, D. et al. Digoxin downregulates NDRG1 and VEGF through the 
inhibition of HIF-1alpha under hypoxic conditions in human lung 
adenocarcinoma A549 cells. Int J Mol Sci 14, 7273-7285 (2013). 
112. Quann, K. et al. Caveolin-1 is a negative regulator of tumor growth in 
glioblastoma and modulates chemosensitivity to temozolomide. Cell Cycle 12, 
1510-1520 (2013). 
113. C., C.E. et al. Involvement of the TGFβ pathway in the regulation of α5β1 
integrins by caveolin‐1 in human glioblastoma. International Journal of 
Cancer 131, 601-611 (2012). 
114. Bailey, K.M. & Liu, J. Caveolin-1 up-regulation during epithelial to 
mesenchymal transition is mediated by focal adhesion kinase. J Biol Chem 
283, 13714-13724 (2008). 
115. Xie, L. et al. Hypoxia-inducible factor/MAZ-dependent induction of caveolin-
1 regulates colon permeability through suppression of occludin, leading to 
hypoxia-induced inflammation. Mol Cell Biol 34, 3013-3023 (2014). 
116. Daster, S. et al. Induction of hypoxia and necrosis in multicellular tumor 
spheroids is associated with resistance to chemotherapy treatment. Oncotarget 
8, 1725-1736 (2017). 
117. Chiu, W.T. et al. Caveolin-1 upregulation mediates suppression of primary 
breast tumor growth and brain metastases by stat3 inhibition. Cancer Res 71, 
4932-4943 (2011). 
 
